Correction to: PharmacoEconomics 10.1007/s40273-019-00829-x {#Sec1}
===========================================================

Due to a single error in the annual cost of sarilumab the following needs to be corrected in the article.

The last line of the results section of the abstract should read "The cost per additional responder for baricitinib in patients with inadequate response to a TNFi was substantially lower than all other treatments for all three ACR response criteria at 12 weeks (ACR20: \$US129,672; ACR50: \$US237,732; ACR70: \$US475,464), among the lowest at 24 weeks for ACR20 and ACR50 (\$US167,811 and \$US259,344, respectively), and similar to other products at ACR70 (\$US570,557)."

In Sect. 3.2, the 3rd sentence of the last paragraph should read "For ACR70 at 24 weeks, tocilizumab, abatacept and sarilumab had the lowest cost per responder followed by baricitinib."

In the Discussion, the 5th sentence of the first paragraph should read "At 24 weeks, baricitinib was second to tocilizumab for ACR20 and ACR50, and fourth to tocilizumab, abatacept and sarilumab for ACR70."

In Table 2, columns 2 and 3, the annual drug cost of sarilumab should be \$43,533. In Table 2, columns 6 and 7 the total costs for sarilumab should be \$43,788 and \$43,656, respectively.

In Table 5, column 2, the annual cost of sarilumab for ACR20, ACR50 and ACR70 endpoints should be \$43,966. In Table 5, column 5, the cost per additional responder for sarilumab for ACR20, ACR50 and ACR70 endpoints should be \$169,098, \$274,785 and \$549569, respectively. In Table 5, column 8, the cost per additional responder for sarilumab for ACR20, ACR50 and ACR70 endpoints should be \$183,190, \$274,785 and \$549,569, respectively.
